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Abstract
Many prescribed treatments for children have not been adequately
tested in children, sometimes resulting in harmful treatments being
Jasmin Khan-Boluki
1
Ferdinand Hundt
2
given and beneficial treatments being withheld. In the absence of spe-
cific trial-based data in children, results of studies in adults are extra-
polated, which is often inappropriate because children have different 1 Hexal Biotech
ForschungsGmbH,München,
Germany
range of diseases and metabolize medications differently. Trials in
children are more challenging than those in adults and the pool of eli-
gible children entering trials is often small. Children must have at last 2 Sanofi-Aventis Deutschland
GmbH, Berlin, Germany the same rights as adults in relation to receiving treatment with medi-
cinal products that have been fully tested. The need for more studies
to obtain paediatric information for medicines used in children is now
a matter of consensus on a global basis and is considered a public
health priority.
Therfore a survey was performed in university hospitals in Germany
targeting the current and future situation of children in clinical trials.
Thequestionnaireofthissurveywassentto68paediatricdepartments
in 31 university clinics in Germany with a respond rate of 27% with re-
spect to 18 returned questionnaires.
With regard to new laws, guidelines and strong governmental support
and funding an increasing number of clinical trials is expected. Surpris-
ingly, the number of trials in the paediatric population remains un-
changed within a period of 4 years (2005-2008). Added to the surveys
performed within the pharmaceutical industry from Heinrich and Hark
thenumberoftrialsinchildrenremainsunchangedevenwithinaperiod
of 9 years (2000-2008). The efforts undertaken by the government re-
garding funding and supporting KKS (Coordinating Centers for Clinical
Trials) and affiliated PAED-Net (Pediatric Network on Medication Devel-
opment and Testing in Children and Adolescents at KKS) appear to be
insufficient. Beginning of this year the legal framework with the urgent
expected “Paediatric Regulation” was established. May be the imple-
mentation by clinicians and pharmaceutical industry will improve the
current situation.
Keywords: survey, paediatric trials, paediatric regulation, KKS, PAED-
Net
Zusammenfassung
Zahlreiche Medikamente wurden bisher nicht ausreichend an Kindern
untersucht, dies kann zu einer gesundheitsgefährdenden Behandlung
von Kindern führen bzw. es werden Kindern wichtige Medikamente
vorenthalten. In Ermangelung von studienspezifischen Daten in der
Pädiatrie werden Ergebnisse aus Studien mit Erwachsenen auf Kinder
übertragen.Diesistoftunsachgemäß,daz.B.KindergegenüberErwach-
senenunterschiedlicheErkrankungsbereichehabensowieMedikamente
unterschiedlich abbauen. Weiterhin sind Studien mit Kindern, im Ver-
gleich zu Studien mit Erwachsenen, schwieriger durchzuführen, zumal
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Kindern die gleichen Rechte zugestanden werden wie Erwachsenen in
Bezug auf sorgfältig entwickelte Arzneimittel. Der Bedarf an klinischen
StudieninderPädiatrieistinternationalerKonsensundzueinerPriorität
der Volksgesundheit geworden.
Zur Situation und Teilnahme von Kindern in klinischen Studien wurde
im Frühjahr 2007 eine Befragung in universitären Kinderkliniken in
Deutschlanddurchgeführt.EinFragebogenwurdean68Kinderkliniken
in31Universitätsklinikengesandt,davonantworteten18Kliniken,dies
entspricht einer Rücklaufrate von 27%.
Unter Berücksichtigung der aktuellen Gesetzgebung, EU-Richtlinien,
staatlicher Unterstützung und Finanzierung, wurde eine Zunahme an
klinischen Studien in der Pädiatrie erwartet. Erstaunlicherweise verän-
dert sich die Anzahl der pädiatrischen Studien in einem Zeitraum von
4Jahren(2005-2008)nicht.DieErgebnissesindvergleichbarmitdenen
der Befragungen von Heinrich und Hark, die 2000 und 2005 innerhalb
der pharmazeutischen Industrie durchgeführt wurden. Werden die
entsprechendenBefragungsperiodenzusammengefaßt,bleibtdieAnzahl
von klinischen Studien mit Kindern über einen Zeitraum von 9 Jahren
(2000-2008) unverändert.
Die staatlichen Bemühungen, Institute wie KKS und PAED-Net (in Uni-
versitätskliniken auf Studien spezialisierte Zentren) zu unterstützen
und zu finanzieren scheinen nicht ausreichend zu sein. Die dringend
erwartete„PaediatricRegulation“wurdeAnfang2007eingeführt;damit
wirddieDurchführungvonklinischenStudienanKindernfürdiemeisten
Arzneimittel zur Pflicht. Deren Umsetzung von Seiten der Kliniker und
der pharmazeutischenIndustrie sollte eine Verbesserung der Situation
zur Folge haben.
Introduction
The use of unlicensed and off label medicine in children
is widespread and is still an increasing concern within
the last years. In the EU 50% or more of medicines used
in children have never been studied in this population
[1], [2], but only in adults, not necessarily in the same
indication (or the same disease). Studies have brought
tolightahighproportiononunlicensedandoff-labeluse,
reaching up to 72% of all prescriptions and 93% of all
paediatric patients [3], [4]. Sick children have a right to
treatment with medications for which the dosage, effect-
iveness and side effects have been systematically inves-
tigated. However, the majority of medications that are
regularly given to children have not been tested and offi-
cially approved for this special age group. It is typical to
transfer the results collected in adults onto children.
However, due to differences in metabolism and body
structure of children compared with adults [5], this prac-
tice does not ensure that children are being treated ac-
cording to the current level of medical knowledge and
with the minimum possible risk of side effects.
Certaindiseasesarecharacteristicallychildhooddiseases
andsomeaningfulresearchonthemneedstobeconduc-
ted on children. Furthermore, there are well known
problems in extrapolating pharmacological data from
adultstochildrenowingtometabolicdifferencesbetween
childrenandadults.Theresponsesofadultsandchildren
to many drugs have much in common, but children are
certainly not small adults. There are particular examples
which illustrate that the response can differ markedly
between adults and children: Different pathophysiology
(e.g. surfactant deficiency), different variant of disease
(e.g. migraine, epilepsy), different pharmacodynamics
(e.g.ciclosporin),different“host”response(e.g.pneumo-
nia, leukaemia), different adverse drug reactions (e.g.
thalidomide, tetracycline).
Children must have at last the same rights as adults in
relation to receiving treatment with medicinal products
that have been fully tested. To ensure that children are
notexposedtounnecessaryrisks,controlledclinicaltrials
are required to determine the most appropriate dose in
children of different ages. Paediatric trials are costly in
time and money, may need a new formulation, and are
fraught with ethical challenges.
Giventherareoccurrenceofmostdiseasesinchildhood,
especially in oncology, conducting clinical trials is expen-
sive and interminable due to the limited number of pa-
tients.InadditiontheconductofclinicaltrialsinGermany
hasbecomemoredifficultand,atleastinthepreparation
of a trial, also more timeconsuming since August 2004
asaconsequenceofthe12
threvisionoftheGermanDrug
Law (AMG) – based on the Directive 2001/20/EC [6].
EspeciallythepreparationofanInvestigationalMedicinal
ProductDossier(IMPD)isanadditionaltask,whichcould
be difficult to perform for sponsors of non commercial
trials.Nothinghaschangedbytheimplementationofthe
Directive 2005/28/EC [7] regarding the conduct of non
commercial trials and no specific regulation on EC level
in this respect can be expected as still of today only a
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cial trials” (June 2006) is available.
In addition, historically several patient populations, chil-
drenandwomenmostprominently,havebeenunderrep-
resented in clinical investigations [8]. In 1995 70-80%
of all new medicinal products approved were still not la-
belled for use in children [9].
Theneedformorestudiestoobtainpaediatricinformation
for medicines used in children is now a matter of con-
sensusonaglobalbasisandisconsideredapublichealth
priority.
The Paediatric Regulation (EC) No 1901/2006, entered
into force on 26 January, 2007, aims to improve the
health of Europe’s children by stimulating research and
development of medicines for use in children, ensuring
that medicines used to treat children are appropriately
tested and authorised. All new applications for MA (Mar-
keting Authorisation) must include results of studies
conductedincompliancewithaPIP(PaediatricInvestiga-
tion Plan), except for those with a waiver or deferral. The
PIP should be submitted no later than the completion of
the relevant human pharmacokinetic studies in adults.
This obligation applies 18 months after entry into force
of the Paediatric Regulation, as of July 2008. From now
on Pharmaceutical Companies will be required by this
European law to provide paediatric data for all new MAA
(MarketingAuthorisationApplications)withtheexemption
of: generics, hybrid medicinal products, biosimilars and
medicinal products containing one or more active sub-
stancesof well-establisheduse, homeopathicand (tradi-
tional) herbal medicines [10].
Implementation of the KKS (Coordinating Centres for
Clinical Trials) and PAED-Net, a “Pediatric Network on
Medication Development and Testing in Children and
AdolescentsatKKS”isaninitiativeoftheFederalMinistry
for Education and Research in Germany (BMBF). PAED-
Net is a network of experts to professionally plan and
performpaediatricstudies.Paediatrictrialsaresupported
in separate special modules. The centers are adminis-
trated by a central coordinating unit in Mainz [11]. It is
intendedtobeaplatformfortransparent,patient-oriented
development of new drugs and therapeutic principles in
Germany [12].
The German Federation of the pharmaceutical industry
(BPI) disseminated a questionnaire to 330 pharmaceut-
ical companies concerning experience with clinical trials
and children in 1998. The feedback rate was significant
low, only10.6% respondedaccountingfor35 companies
[13], as a consequence the answers were not represent-
ative.
In2000and2005twosurveysonclinicaltrialsinchildren
were carried out among companies belonging to the
German association of research-based pharmaceutical
companies (VFA). The objective was to collect the extent
of clinical trials conducted in children and the evaluation
of the experience the pharmaceutical industry made in
thisrespect[14],[15].Bothsurveys,withagoodresponse
rate, have shown, that the amount of studies might stay
at a constant level from 2000-2005.
Methods
To provide a status report on the current and future situ-
ation of clinical trials in children a survey was performed
inpaediatricdepartmentsofuniversityclinicsinGermany,
covering a time period of at least 4 years (last 2 years,
current status and planned next 2 years). The question-
naire was based on the surveys performed by Heinrich
and Hark within the pharmaceutical industry but was
modified in cooperation with the PAED Net according to
clinicalrequirements.Itconsistsof21 questionsandthe
processing time was assumed by 15-30 minutes.
In February 2007 the questionnaire was sent to 68 pae-
diatric departments in 31 university clinics in Germany
and 18 (27%) centers responded to the survey.
Questionnaire
The paediatricians were asked, if clinical trials with chil-
dren were conducted currently, within the last 2 years or
if clinical trials are planned within the next 2 years. For
eachtimeperiodthenumberoftrialsandindicationswas
asked for. Further on the respondent was asked if the
trials were conducted with or without support of PAED-
Net/KKSand/orCROs(ClinicalResearchOrganisations),
if the trials were Investigator Sponsored Trials (IST) or
Investigator Initiated Trials (IIT) and/or if the trial were in
cooperationwiththepharmaceuticalindustry.Furtheron
it was asked for reasons of good or bad conduct of trials,
difficulties to recruit suitable patients and if and why a
trial was refused by the Ethic Committees (EC) and/or
the German Federal Institute for Drugs and Medical
Devices (BfArM)/Paul Ehrlich Institute (PEI).
Results
18 questionnaires were sent back from the following
faculties: general paediatrics (7), paediatric cardiology
(4), paediatric psychiatry (2), neonatology (2), paediatric
surgery(1),paediatricneurology(1)andpaediatriconco-
logy (1). In total 2 KKS were involved in answering the
questionnaire.
Conduct of clinical trials in children
within 2005-2006
All18centersrespondingtothesurveyperformedclinical
trials in children within 2005-2006. A total of at least
229 studies in 18 centers were reported, but in case of
multicenter studies multiple mentions from different
centers are possible. 56% (10/18) of the centers per-
formedupto5trials,6%(1/18)ofthecentersconducted
up to 10 trials, 11% (2/18) of the centers performed up
to 20 trials and in 17% (3/18) of the centers were up to
65 trials performed (mean: 14, median: 4, missing data
in 2 cases).
Seven centers (39%) performed the studies without par-
ticipationofPAED-Net/KKS,and/orCROs.Elevencenters
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centers worked with PAED-Net/KKS and 4 centers with
CROs (multiple mentions were possible, 2 centers with
missing data). Support of PAED-Net/KKS and/or CROs is
nearly equal distributed per center but the total number
of trials was much higher in the PAED-Net/KKS group
than in the CRO group (93 versus 27).
Current situation
Currently,twocentersdonotconductanytrialinchildren,
but in the remaining sixteen centers a total of at least
135studieswerereported,incaseofmulticenterstudies
multiple mentions were possible. 56% (10/18) of the
centers perform up to 5 trials, 6% (1/18) of the centers
conduct up to 10 trials, 11% (2/18) of the centers per-
form up to 20 trials and in 6% (1/18) of the centers up
to40trialsandupto65trialsrespectivelyareperformed
(mean: 9, median: 3, missing data in 1 case). Six centers
(38%)performedthetrialswithoutparticipationofPAED-
Net/KKS, and/or CROs. Ten centers (62%) were suppor-
ted by these organisations whereas 5 centers worked
with PAED-Net/KKS and 4 centers with CROs (multiple
mentions were possible, 2 centers with missing data).
SupportofPAED-Net/KKSand/orCROsisequallydistrib-
uted per center but the total number of trials was much
higherinthePAED-Net/KKSgroupthanintheCROgroup
(52 versus 11).
Conduct of clinical trials in children
planned within 2007-2008
Only two centers have no trials planned for the forthcom-
ing 2 years but in the remaining sixteen centers a total
of at least 124 studies are planned to conduct (in case
of multicenter studies multiple mentions were possible).
44% (8/18) of the centers have planned to conduct up
to 5 trials, 11% (2/18) of the centers will perform up to
20trials,and6%(1/18)ofthecentersplanupto40trials
(mean: 6, median: 4, missing data in 5 cases (28%)). Six
centers(38%)plantoperformthetrialswithoutparticipa-
tion of PAED-Net/KKS, and/or CROs. Nine centers (56%)
will conduct the trials supported by these organisations
(1 (6%) center with missing data). Four centers will work
with PAED-Net/KKS and two centers with CROs (multiple
mentions were possible, 3 centers with missing data).
Support of PAED-Net/KKS is double as high as support
by CROs which is represented by the total number of
studies (35 versus 3).
Noincreaseinclinicaltrialswithchildreninthelastyears
is indicated (Figure 1). Indeed, it seems to be a slight
decrease in the future which could be explained by an
incomplete or unknown planning of clinical trials for the
next years. With respect to new laws, guidelines and
strong governmental support an increasing number of
clinical trials in children could have been expected. Sur-
prisingly the number of trials seems to be unchanged or
even decreasing within a period of at least 4 years.
As factors of success or failure for conduct of paediatric
trials the items in Table 1 and Table 2 were listed.
Table 1: Items of success for conduct of clinical trial
Table 2: Items of failure for conduct of clinical trial
Further on reasons for a good conduct of clinical trials in
the paediatric field were mentioned additionally: rapid
availability of staff that cares on potential patients for
inclusion, convincing study design and motivation of
participating physicians.
Reasons for a bad conduct of clinical trials in the paedi-
atric field were mentioned also: untypical setting/study
design for paediatric indications, no money for GCP con-
form studies (oncology), lack of motivation, physicians
not interested in project and political decisions.
50% of the responders had no difficulties to include pa-
tients,whereas50% of the responders had difficultiesto
includesuitablepatientsintothestudiesforthefollowing
reasons: complex study design, enrolment period too
short and prohibited concomitant medication.
The question, if clinical trials were refused by the Ethical
Committee or by the German Health Authorities (Federal
Institute for Drugs and Medical Devices, BfArM/Paul
Ehrlich Institute, PEI) was clearly answered with no by
89% (16/18); only one center (1/18) had experienced
that a project was refused, and there was one missing
answer (1/18).
Surprisingly, although the number of answers is limited,
only one single project was rejected by EC or Health Au-
thority in only 6% of the studies. This could demonstrate
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a good quality of the study preparation (e.g. quality of
medicinal product, study design and study protocol, in-
formed consent) and good collaboration with EC and
competent authority.
To identify the purpose of the clinical trials in children,
the question was asked if the results of these clinical tri-
alswereusedforinitialregistrationofamedicinalproduct
or if the results were used for an extension of indication
in children. 67% (12/18) of the responders answered
this question: 33% (6/18) used the trials for an initial
registration and in 56% (10/18) the result of the trials
were intended for an extension of the indication for chil-
dren (with 28% (5/18) missing data). Nearly twice of the
clinical trials conducted in children are performed with
medicinal products already registered in adults or in
other indications.
Discussion
Thequestionnaireofthissurveywassentto68paediatric
departmentsin31universityclinicsinGermany,unfortu-
natelytherewasonlyaresponseof18paediatricdepart-
ments although the centers were reminded by mail and
additionallycontacted by phone. Despite the lackof time
which some of the centers mentioned, what are the
reasons for such a low and disappointing response?
Similarsurveyswereperformedwithinthepharmaceutical
industry with a much better response rate. It could be
assumed that the pharmaceutical industry is more inter-
ested in showing that they are conducting clinical trials
in children than the treating paediatricians. The results
ofbothsurveysfromHeinrichandHarkperformedwithin
the pharmaceutical industry were confirmed by each
other.FurthermorethissurveyundertakenwithinGerman
university departments shows similar results. Therefore
it can be concluded that the collected data are reliable.
The three surveys consulted both relevant kinds of insti-
tutions and can therefore adequately mirror clinical re-
search in the paediatric population in Germany within a
time frame from 2000-2008. Hark and Heinrich have
shownintheirsurveysperformedwithinthepharmaceut-
ical industry that the number of trials in the paediatric
population seems to stay constant for a time period from
2000-2005.Theinterpretationoftheresultsofthissurvey
within paediatric departments of German university hos-
pitals indicates that the amount of studies in Germany
mightalsostayataconstantlevelwithinthenext2years.
There is a slight trend in decreasing the number of trials
which could be explained by an incomplete or unknown
planning for the next years. But with respect to new laws,
guidelinesandstronggovernmentalsupportanincreasing
number of clinical trials in children was and is expected.
Surprisingly the number of trials seems to be unchanged
withinaperiodofatleast4years(thissurvey)andadded
to the surveys from Heinrich and Hark, within a period of
9 years (2000-2008).
The results of these three surveys show that the Clinical
Trial Directive (2001/20/EC), implemented in 2004 had
no increasing effect on the number of clinical trials per-
formed in Germany in the paediatric population so far.
The European Organisation for Research and Treatment
of Cancer (EORTC), the largest independent cancer re-
search network in Europe, recently analysed the effect
oftheEUClinicalTrialDirective:Thenumberofnewtrials
fell from 19 in 2004 to 7 in 2005 (63%), and a third
fewer patients were enrolled. Simultaneously, trial costs
increased by 85%. Trial initiation was about 5 months
slower than in 2004, mostly the result of increased
workload of Ethic Committees [16].
The EU Clinical Trial Directive was implemented to im-
prove the quality of clinical trials and assure the safety
andwell-beingoftrialsubjects.Thedecreaseofnewnon-
commercial paediatric trials in Europe – essential for
optimisingpaediatrictreatments–sinceimplementation
of the EU Clinical Trial Directive is also confirmed by
Cannell 2007 [17].
On the one hand, the EU Clinical Trial Directive certainly
improves the quality of clinical trials and assures the
safety andwell-beingof trialsubjects.It emphasisesthat
children represent an especially vulnerable population
with developmental, physiological and psychological dif-
ferencesfromadults,whichmakeage-anddevelopment-
related research important for their benefit. On the other
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example pharmaceutical industry has to build up paedi-
atric expertise and has to train the various development
departments within the relevant aspects of paediatric
drug development [18].
Only few trained paediatric clinical pharmacologists are
availableintheEuropeanUnion[19].Additionally,Assael
confirmed that compared to the US, most studies have
been performed by general paediatricians and not by
physicians specialised in paediatric pharmacology [20]:
there is an urgent need to train paediatric physician sci-
entists in clinical pharmacology.
Although the importance of clinical trials in children is
increasingly recognised by major research groups and
professional bodies worldwide [21], there is still a strong
needtoimprovetheawarenessnotonlyinpublicbutalso
between the paediatricians. It often seems more accept-
able to use untested medicationson childrenas “routine
clinical care” rather than enrol eligible children in a rele-
vant clinical trial. A survey among paediatricians has
shown, that there is concern about off label prescribing
and that there is a need for clinical trials in children, but
there was only a low acceptancefor such studies. During
2003-2004 all hospital based paediatricians were con-
tacted in Scotland within a survey; this survey had a re-
sponserateof59%(257questionnairesweredistributed
and151werereturned).Althoughonlyhalfoftherespond-
ents believed that the use of off label medicines disad-
vantages their patients, a lager number expressed con-
cerns about safety and efficacy issues, reporting high
levels of treatment failure and Adverse Drug Reactions
(ADR). Unexpectedly only a third of respondents thought
that specific formulations were required, highlighting an
unawarenessofthecurrentsituationwherepharmacists
overcomethelackofpaediatricformulationsbysupplying
extemporaneous preparations, imported medicines, or
unlicensedspecialproducts.Onlyhalfoftherespondents
believedthatmedicinesshouldundergotrialsinchildren,
citing as the reasons for this less enthusiastic attitude
“that there was already a significant level of empirical
knowledge available” [22]. Definitely, there are many
other references stating that clinical trials are necessary
and required in the paediatric population but there are
still 30% of hospital based paediatricians within a
European country treating children and believing that
these trials are not essential.
Considerationofthisapparentlackofenthusiasmforthe
necessity of clinical trials in children, actions to promote
requirements for safe and efficious medicines in the
paediatric population has to be strengthen particularly
with regard to the “experts”: the paediatricians. But not
only the awareness of the “experts” but also the aware-
ness among parents, patient groups and the public has
to be increased.
“Although there is a lot to do, some of the German Paedi-
atric Specialists are optimistic: Within the next 10 to 15
years there will be sufficient meaningful clinical trials for
children and adolescents” [23]. Changes within a period
of 10-15 years is interminable and not very optimistic.
Additionally it is doubtful to reach this goal within the
giventimeframetakingintoconsiderationthatinstitutions
like KKS and PAED-Net exists since 9 years and 6 years
respectively. Further on the European Union is 13 years
behindcomparedtotheUS,wherethePediatricRulewas
implemented in 1994. All this indicates that there is a
chance for improvement of the situation, but it will last
for many years and perhaps will overrun its time. Begin-
ning of 2007 the legal framework was established, now
the implementation by clinicians and pharmaceutical in-
dustry is strongly required.
Conclusions
It is over 30 years since the term “therapeutic orphan”
was used [24], [25]. Children have the same rights as
adults to receive medicines that have been formally
tested to ensure efficiency and safety. To improve such
situation the joint effort of paediatricians, governmental
organisations, the pharmaceutical industry, and any
relevant bodies or individuals is mandatory in order to
ensurethatchildrendonotremain”therapeuticorphans”.
Commoninitiativesofpoliticians,paediatricians,pharma-
ceutical industry and health authorities have to enforce
thenecessityforclinicaltrialsinthepaediatricpopulation.
Better education of the medical community and the
publicisneededabouttherationaleandbenefitsoftrials
and the potential dangers of using health-care interven-
tionsthathavenotbeenappropriatelystudied.Negatively
biased media coverage about clinical trials involving
children needs to be balanced with public-awareness
campaigns about the societal benefits of randomised
controlled trials. The possible harm from unpredicted
adverse events because of a lack of paediatric trials has
tobehighlighted.Astheneedanddemandforpaediatric
clinical trials, paediatricians and researchers must find
strategiestoovercomebothparents’anddoctors’barriers
to trial participation.
Testing medicinal products has historically been low on
the pharmaceutical industry’s priority list. This has been
due to lack of legislation, financial incentives, and fear
of harm to children. As the US and Europe regulators
mandate and guide the legal, licensing, and ethical
framework for paediatric trials, it is hoped that the situ-
ation will change now and all (pharmaceutical industry
and researchers) will rise to the challenge and prepare
foraneweraofmedicinalbenefitforthechildren.Europe-
wide clinical trials must be faster, safer, easier and
cheaper for both industry and academic sponsors.
To improve this disappointing situation the following
proposals are recommended:
• Create and strengthen awareness among paediatri-
cians, parents, patient groups and public
• Buildupinternationalnetworkand“expert”knowledge
by paediatricians and pharmaceutical industry
• Increase public funding and control progress
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creased efforts and costs in conducting clinical trials
with children
Children deserve better: Children are our future!
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